Delta-Sarcoglycan–Related Limb-Girdle Muscular Dystrophy R6 (LGMDR6)

Delta-sarcoglycan–related limb-girdle muscular dystrophy R6 (LGMDR6) is a rare, inherited muscle disease. It weakens the large muscles around the hips, thighs, shoulders, and upper arms (the “limb girdles”). It happens when there are disease-causing changes (mutations) in a gene called SGCD, which makes the delta-sarcoglycan protein. This protein is one of four parts of the sarcoglycan complex, a stabilizing “anchor” in the muscle cell membrane that connects the inside of the muscle fiber to the outside support network through the dystrophin–glycoprotein complex. When delta-sarcoglycan is missing or faulty, the whole complex becomes unstable, muscle fibers are injured during everyday use, and weakness slowly gets worse over time. In many people, the heart muscle can also be affected, leading to cardiomyopathy. LGMDR6 is autosomal recessive, meaning a child develops the condition when they inherit one faulty SGCD gene from each parent. BioMed Central+3Orpha+3PubMed+3

Delta-sarcoglycan–related limb-girdle muscular dystrophy is a rare, inherited muscle disease. A change (mutation) in the SGCD gene makes the delta-sarcoglycan protein faulty or missing. Delta-sarcoglycan normally sits in a protective ring of proteins (the sarcoglycan complex) that helps connect each muscle cell to its outer support structure. When this protein is weak or absent, the muscle cell membrane becomes fragile. Over time, everyday use leads to tiny tears, inflammation, scarring, and gradual loss of muscle strength—especially around the hips, thighs, shoulders, and upper arms. Some people also develop heart muscle weakness (dilated cardiomyopathy) and may need routine heart checks and treatment. There is no cure yet, but many supportive treatments can slow complications, protect the heart and lungs, and keep function for longer. PMC+3Muscular Dystrophy UK+3NMD Journal+3

---

Other names

This condition appears in the medical literature under several names. Knowing these helps when you read older papers or search databases:

• LGMDR6 (current nomenclature)

• LGMD2F (older name, still widely used)

• Delta-sarcoglycanopathy

• SGCD-related limb-girdle muscular dystrophy

• Limb-girdle muscular dystrophy due to delta-sarcoglycan deficiency Orpha+1

---

Types

There is only one genetic cause (mutations in SGCD), but people can look quite different in age of onset and severity. Clinicians often describe clinical patterns rather than formal subtypes:

1. Childhood-onset classic LGMDR6 – Weakness starts in the first decade, walking becomes difficult over the teen years, and heart involvement may appear. NCBI

2. Adolescent/young-adult onset – Milder early course with slower decline; heart checks are still important. Muscular Dystrophy UK

3. Cardiomyopathy-predominant pattern – Some individuals show early dilated cardiomyopathy with or without obvious limb weakness at first; this reflects delta-sarcoglycan’s high expression in heart. PMC+1

4. Respiratory-involvement–predominant pattern – Later in the course, breathing muscles can weaken; some people need assisted ventilation. NCBI

These patterns reflect the same underlying disease and help teams plan monitoring and care. PubMed

---

Causes

“Cause” here means the genetic changes that produce disease and factors that influence how severe it looks. The root cause is always pathogenic variants in SGCD.

1. SGCD missense variants (a single “letter” change alters one amino acid and weakens the protein). BioMed Central

2. SGCD nonsense variants (a change creates a premature stop signal; the protein is cut short). Frontiers

3. Frameshift variants (small insertions or deletions shift the reading frame and disrupt the protein). PMC

4. Splice-site variants (errors at intron–exon junctions mis-splice the RNA). PMC

5. Large exon or whole-gene deletions/duplications (copy-number changes that remove or duplicate SGCD segments). BioMed Central

6. Compound heterozygosity (two different SGCD variants—one from each parent—combine to cause disease). BioMed Central

7. Homozygosity from parental relatedness (consanguinity) (the same variant inherited from both parents). Frontiers

8. Secondary loss of the sarcoglycan complex (a delta-sarcoglycan defect destabilizes α/β/γ partners, worsening membrane fragility). BioMed Central

9. Failure of the dystrophin–glycoprotein link (DGC uncoupling increases mechanical stress injury with every contraction). NCBI

10. High mechanical load on muscles (hard exercise can unmask or aggravate weakness in fragile fibers). Mechanistic inference consistent with DGC instability. BioMed Central

11. Cardiac expression of SGCD (heart muscle is vulnerable, predisposing to dilated cardiomyopathy). PMC

12. Modifier genes (other muscle-membrane or repair genes may modulate severity—an active research area). ScienceDirect

13. Founder variants in certain populations (rare, but some communities have recurring SGCD variants). BioMed Central

14. Protein misfolding and ER stress (certain variants misfold the protein and trigger degradation). Mechanistic model discussed in reviews. PubMed

15. Disrupted membrane repair signaling (loss of sarcoglycans perturbs signaling around the sarcolemma). PubMed

16. Inflammatory responses to fiber injury (repeated damage invites secondary inflammation and scarring). BioMed Central

17. Age-related cumulative damage (weak membranes accumulate micro-tears over years). PubMed

18. Arrhythmia-prone myocardium (cardiac electrical instability emerges as the heart dilates). NCBI

19. Inadequate complex assembly in the membrane (delta-sarcoglycan defects block proper sarcoglycan complex insertion). BioMed Central

20. Loss of linkage to extracellular matrix (weakened connection to laminin-2 and ECM makes fibers less resilient). NCBI

---

Common symptoms and signs

1. Trouble rising from the floor or a chair – Thigh and hip muscles are weak, so people push on their legs to stand (Gowers’ maneuver). MedlinePlus

2. Waddling gait – Hip weakness makes walking side-to-side and tiring. MedlinePlus

3. Difficulty climbing stairs or running – Tasks that need powerful proximal muscles become hard early. MedlinePlus

4. Shoulder weakness – Lifting arms overhead or carrying objects is hard as shoulder-girdle muscles weaken. MedlinePlus

5. Scapular winging – Shoulder blades stick out because stabilizing muscles are weak. MedlinePlus

6. Calf enlargement (“pseudohypertrophy”) – Calves look big from fat and scar tissue replacing muscle. PubMed

7. Frequent falls and fatigue – Weak muscles tire faster and balance is reduced. MedlinePlus

8. Joint tightness (contractures) – Ankles, knees, or elbows may stiffen over time from muscle shortening. MedlinePlus

9. Lower-back curve (lordosis) or scoliosis – Trunk weakness changes posture and spine alignment. MedlinePlus

10. Heart problems (dilated cardiomyopathy) – The heart may enlarge and pump weakly, causing breathlessness, swelling, or palpitations. PMC+1

11. Abnormal heart rhythms – Skipped beats or fast rhythms can occur in some people. NCBI

12. Shortness of breath with activity – Either the heart or respiratory muscles (or both) contribute. NCBI

13. Night-time hypoventilation – Shallow breathing during sleep can cause morning headaches and daytime sleepiness later in the disease. Muscular Dystrophy UK

14. Muscle pain or cramps after exertion – Fragile membranes make exercise recovery harder. PubMed

15. Progressive loss of walking ability – Mobility aids or a wheelchair may be needed as weakness advances. PubMed

---

Diagnostic tests

A) Physical examination (what a clinician checks in the clinic)

1. Gait assessment – Doctors watch walking for a waddling pattern and toe-walking; this reflects hip and thigh weakness. MedlinePlus

2. Gowers’ sign – Standing up from the floor by “climbing” on the thighs shows proximal weakness. MedlinePlus

3. Scapular winging check – Prominent shoulder blades signal shoulder-girdle weakness typical of LGMD. MedlinePlus

4. Calf size and firmness – Bulky, firm calves suggest pseudohypertrophy. PubMed

5. Joint range-of-motion – Contractures at ankles, knees, and elbows are measured and tracked over time. MedlinePlus

B) Manual and bedside functional tests

6. Manual muscle testing (MRC grading) – Grading strength by hand gives a baseline and follows change across visits. Europe PMC

7. Timed function tests – Timed up-and-go, 10-meter walk, and stair-climb time quantify everyday abilities simply. Europe PMC

8. Six-minute walk distance – Measures endurance and fatigue; helpful for tracking change and clinical trials. Europe PMC

9. Pulmonary function tests at the bedside – Forced vital capacity and peak cough flow spot early breathing muscle weakness. Muscular Dystrophy UK

10. Clinical cardiac screening – Blood pressure, pulse, and signs of heart failure guide urgent testing. NCBI

C) Laboratory and pathological tests

11. Serum creatine kinase (CK) – High CK suggests muscle fiber breakdown; common in sarcoglycanopathies. PubMed

12. Liver enzymes (AST/ALT) – Can be elevated from muscle, not just liver, and help support a muscle source. MedlinePlus

13. Genetic testing for SGCD – Sequencing finds missense/nonsense/splice/frameshift variants; MLPA or CNV analysis detects large deletions/duplications. This confirms the diagnosis. NCBI+1

14. Targeted neuromuscular gene panels or exome – Efficient when several LGMD genes are possible; panels include SGCD. NCBI

15. Muscle biopsy (histology) – Shows a “dystrophic” pattern: fiber size variation, necrosis, and replacement by fat and scar. Europe PMC

16. Immunohistochemistry / western blot – Demonstrates absent or severely reduced delta-sarcoglycan and often secondary reduction of the other sarcoglycans; dystrophin is usually preserved—this pattern points to an SGCD-related sarcoglycanopathy. Europe PMC+1

D) Electrodiagnostic and cardiopulmonary tests

17. Electromyography (EMG) – Shows a myopathic pattern (small, brief motor unit potentials), supporting muscle fiber disease rather than nerve disease. Europe PMC

18. Electrocardiogram (ECG) and Holter monitoring – Detects conduction issues or arrhythmias related to cardiomyopathy risk. NCBI

19. Echocardiography – Ultrasound of the heart to look for chamber enlargement and reduced pumping function. (Often repeated over years.) PMC

E) Imaging tests

20. Cardiac MRI and skeletal-muscle MRI – Cardiac MRI quantifies scarring and function in dilated cardiomyopathy; muscle MRI shows typical patterns of muscle involvement that can support the diagnosis and guide biopsy site. PMC+1

Non-pharmacological treatments (therapies & other approaches)

1. Individualized physical therapy (PT).
   Gentle, regular movement maintains range of motion, delays contractures, and supports safer mobility; avoid painful over-exertion. A neuromuscular-trained PT can design low-impact routines (stretching, positioning, hydrotherapy) and teach joint-protection techniques. Muscular Dystrophy Association+1

2. Occupational therapy (OT).
   OT adapts daily tasks (self-care, school/work, home set-up), introduces energy-saving strategies, and recommends aids (grab bars, adaptive utensils) to keep independence and prevent falls. Muscular Dystrophy Association

3. Respiratory care & cough support.
   Regular lung checks, breathing tests, airway-clearance training, breath-stacking, and (when needed) assisted cough/NIV help prevent chest infections and nighttime low oxygen. PMC

4. Cardiac surveillance & lifestyle.
   Yearly (or advised) ECG/echo detects early heart weakness; salt control, fluid balance, and graded activity protect the heart alongside medication when indicated. NMD Journal+1

5. Orthotic support (AFOs, stance control braces).
   Light braces support weak muscles, improve gait safety, and delay contractures. Seating specialists can optimize wheelchair posture and pressure relief. Muscular Dystrophy Association

6. Hydrotherapy / aquatic exercise.
   Warm-water movement reduces joint load and pain, enabling safe range-of-motion and mild aerobic training. Muscular Dystrophy Association

7. Fall-prevention program.
   Home hazard review, assistive devices, footwear checks, and balance training reduce fracture and hospitalization risk. Cleveland Clinic

8. Nutrition & weight management.
   Balanced calories and protein support muscle and immunity; dietitians also guide constipation prevention and bone health (calcium/vitamin D) given low mobility. Cleveland Clinic

9. Speech/swallow evaluation (when bulbar issues appear).
   Early assessment catches choking risk and supports safe textures, posture, and pacing at meals. Cleveland Clinic

10. Contracture management.
    Daily stretching, splints, and guided positioning slow tendon tightening. Serial casting and botulinum toxin are case-by-case. Muscular Dystrophy Association

11. Pain & fatigue self-management.
    Heat/cold, gentle massage, pacing, and sleep hygiene reduce secondary pain and exhaustion without overusing sedating medicines. Cleveland Clinic

12. Pressure-relief strategies.
    Cushions and turning schedules protect skin when sitting/lying longer hours. Muscular Dystrophy Association

13. Education & genetic counseling.
    Explains autosomal-recessive inheritance, options for relatives, and planning for pregnancy. Muscular Dystrophy UK

14. School/work accommodations.
    Ergonomic desks, extra time, elevator access, and remote options help maintain participation and income. Muscular Dystrophy Association

15. Vaccinations & infection prevention.
    Keep influenza, pneumococcal, COVID-19, and Tdap up to date to reduce respiratory setbacks. PMC

16. Mental health support.
    Coping skills, counseling, and support groups reduce anxiety/depression burden and improve adherence to care. Cleveland Clinic

17. Assistive technology.
    Power mobility, transfer devices, and environmental controls preserve independence and safety. Muscular Dystrophy Association

18. Sleep optimization.
    Screen for nocturnal hypoventilation and sleep apnea; optimize sleep environment and schedules. PMC

19. Bone health program.
    Weight-bearing as tolerated, vitamin D/calcium, and fracture-prevention strategies address osteoporosis risk from reduced mobility. Cleveland Clinic

20. Multidisciplinary clinic follow-up.
    Regular combined visits (neuromuscular, cardiology, pulmonology, rehab) coordinate care and catch problems early. NMD Journal

---

Drug treatments

There are no FDA-approved, disease-specific drugs for LGMDR6. Medicines are used to treat heart failure (if it develops), manage symptoms, and prevent complications. Labels below are from accessdata.fda.gov and support use in heart failure; in LGMDR6 they are typically off-label for the muscular dystrophy itself but on-label for the heart condition. Always tailor with your cardiologist/neuromuscular team.

1. Carvedilol (beta-blocker).
   Class: non-selective β-blocker with α1-blockade. Dose: often start 3.125 mg twice daily; titrate as tolerated. Timing: with food; slow uptitration. Purpose: improve survival in systolic heart failure. Mechanism: reduces sympathetic drive, heart rate, and remodeling. Side effects: dizziness, bradycardia, hypotension, fatigue; watch asthma/COPD. Evidence: FDA label indicates benefit in chronic heart failure. FDA Access Data+2FDA Access Data+2

2. Lisinopril (ACE inhibitor).
   Dose: usually 2.5–5 mg daily to start; titrate. Purpose: reduce afterload, slow heart remodeling, improve symptoms/survival. Mechanism: blocks angiotensin-converting enzyme → vasodilation, lower aldosterone. Side effects: cough, high potassium, kidney issues, angioedema; avoid in pregnancy. Evidence: FDA label and trials in systolic heart failure. FDA Access Data+1

3. Sacubitril/valsartan (ARNI).
   Dose: start per label (e.g., 49/51 mg bid or lower depending on prior ACEi/ARB). Purpose: reduce HF hospitalizations and CV death in HFrEF. Mechanism: neprilysin inhibition + ARB increases natriuretic peptides and reduces RAAS tone. Side effects: hypotension, hyperkalemia, angioedema risk; 36-hour ACEi washout required. Evidence: FDA labeling (tablets and “Sprinkle” pediatric pellets). FDA Access Data+1

4. Spironolactone (MRA).
   Dose: often 12.5–25 mg daily. Purpose: survival benefit in advanced HFrEF; edema control. Mechanism: blocks mineralocorticoid receptor → less fibrosis and sodium retention. Side effects: high potassium, kidney dysfunction, gynecomastia. Evidence: FDA label summarizes RALES survival reduction. FDA Access Data+1

5. Eplerenone (MRA).
   Dose: 25–50 mg daily. Purpose: post-MI LV dysfunction or HFrEF, reduces mortality. Mechanism: selective MRA (fewer endocrine side effects vs spironolactone). Side effects: hyperkalemia, renal issues; interacts with strong CYP3A4 inhibitors. FDA Access Data+1

6. Loop diuretics (e.g., furosemide).
   Purpose: relieve fluid overload (edema, breathlessness). Mechanism: blocks Na-K-2Cl in loop of Henle → diuresis. Side effects: electrolyte loss, dehydration, kidney issues, ototoxicity (high doses). Evidence: FDA label supports use in edema/heart failure. Muscular Dystrophy Association

7. ARBs (e.g., valsartan) when ACEi not tolerated.
   Purpose: similar afterload/reverse remodeling benefits. Side effects: hyperkalemia, renal function changes. Evidence: FDA labels for HFrEF/hypertension. FDA Access Data

8. SGLT2 inhibitors (if diabetes/HF present; label-based for HFrEF).
   Purpose: reduce HF hospitalizations and CV death in HFrEF (with or without diabetes). Side effects: genital mycotic infections, volume depletion, rare ketoacidosis. Evidence: FDA labels (dapagliflozin/empagliflozin) include HFrEF indications. (Note: not disease-specific to LGMDR6). AHAS Journals

9. Anticoagulation (select cases).
   Purpose: prevent clots in severe LV dysfunction/AF per cardiology judgment. Risks: bleeding. Evidence: guideline-driven, not LGMDR6-specific. AHAS Journals

10. Vaccines & antibiotics (supportive).
    Purpose: lower respiratory infection risk and treat promptly to avoid setbacks. Evidence: general respiratory-care standards in NMD. PMC

Notes: Corticosteroids are standard in Duchenne but evidence is mixed in sarcoglycanopathies; they are not FDA-approved for LGMDR6 and should be individualized by specialists. Gene therapy trials are ongoing in other LGMD subtypes; none are approved yet for SGCD at the time of writing. ScienceDirect+1

---

Dietary molecular supplements

1. Creatine monohydrate. May improve short-burst muscle performance and fatigue in some neuromuscular disorders; typical doses 3–5 g/day. Monitor kidneys; discuss with your clinician. PMC

2. Coenzyme Q10 (ubiquinone). Mitochondrial cofactor studied in cardiomyopathy and fatigue; doses often 100–300 mg/day with food; may aid exercise tolerance in some. AHAS Journals

3. Vitamin D. Supports bone and muscle; dosing individualized to blood levels (often 800–2000 IU/day maintenance). Cleveland Clinic

4. Omega-3 fatty acids. Anti-inflammatory effects; 1–2 g/day EPA+DHA commonly used; watch bleeding risk on anticoagulants. AHAS Journals

5. Protein optimization (food-first approach). Aim for spread protein intake across meals; dietitian can set targets (~1.0–1.2 g/kg/day unless restricted). Cleveland Clinic

6. Magnesium (if low). Can help cramps/constipation; avoid excess in renal impairment; dose per levels/dietitian. Cleveland Clinic

7. Carnitine (selected cases). May support fatty-acid transport; discuss risks/benefits before use. PMC

8. Antioxidant-rich diet pattern. Emphasize colorful vegetables/fruit, nuts, pulses, whole grains for general cardiometabolic health. AHAS Journals

9. Probiotics/fermented foods. May reduce antibiotic-associated diarrhea when antibiotics are needed for chest infections. PMC

10. Adequate fluids/fiber. Supports bowel health and reduces straining that can worsen fatigue and pain. Cleveland Clinic

---

Immunity-booster / regenerative / stem-cell” drugs

There are no approved stem-cell or “regenerative” drugs for LGMDR6. Be cautious with clinics offering unapproved cell therapies. In the U.S., FDA warns against unapproved stem-cell interventions outside regulated trials. If a clinician suggests any immune-modulating drug, it is for a specific complication (e.g., myocarditis) and not for the genetic muscle disorder itself. AHAS Journals

---

Surgeries and procedures (why and when)

1. Tendon-release surgery (severe contractures).
   When tendons become very tight, releases can improve limb position for comfort, hygiene, or brace fitting. Decisions are individualized after failed conservative care. Muscular Dystrophy Association

2. Spinal surgery (progressive scoliosis affecting function or breathing).
   Seating optimization and bracing come first; surgery is considered when curves threaten lung function or sitting balance. Muscular Dystrophy Association

3. Cardiac devices (ICD/CRT) for selected cardiomyopathy.
   In people with dangerous rhythm risks or dyssynchrony, devices can prevent sudden death or improve pumping coordination. Physiopedia

4. Gastrostomy (feeding tube) when nutrition is unsafe by mouth.
   Used if swallowing is unsafe or intake is too low; improves weight maintenance and reduces aspiration risk. Cleveland Clinic

5. Tracheostomy (advanced respiratory failure, select cases).
   Considered when non-invasive ventilation is inadequate and goals of care support invasive ventilation. PMC

---

Prevention tips

1. Vaccinate per schedule (flu, pneumococcal, COVID-19). PMC

2. Annual cardiology review (earlier if symptoms). NMD Journal

3. Daily stretching and gentle range-of-motion. Muscular Dystrophy Association

4. Falls-proof your home and use appropriate mobility aids. Cleveland Clinic

5. Keep weight in a healthy range; protein at each meal. Cleveland Clinic

6. Practice airway-clearance techniques during colds. PMC

7. Schedule routine dental care to reduce aspiration risks. PMC

8. Protect skin with pressure-relief cushions and regular turns. Muscular Dystrophy Association

9. Maintain sleep routines and screen for nocturnal hypoventilation. PMC

10. Keep a written emergency plan (cardiac and respiratory). NMD Journal

---

When to see a doctor urgently

• New or worsening shortness of breath, swollen ankles, chest pain, or rapid/irregular heartbeat. AHAS Journals

• Nighttime headaches, morning confusion, or daytime sleepiness (possible under-ventilation). PMC

• Trouble swallowing, choking, or frequent chest infections. Cleveland Clinic

• Rapid loss of walking ability, frequent falls, or severe new pain. Muscular Dystrophy Association

---

What to eat (and avoid)

Eat:

• Balanced meals with lean proteins (fish, eggs, legumes), whole grains, colorful vegetables, fruits, nuts, seeds, and healthy oils. Supports muscle, heart, and gut health. Cleveland Clinic

• Adequate calcium and vitamin D sources (dairy/fortified alternatives, safe sun, supplements if low). Protects bones under low mobility. Cleveland Clinic

• Fiber and fluids to prevent constipation (oats, pulses, fruits/veg, water). Cleveland Clinic

Avoid or limit:

• Excess salt (processed foods, salty snacks) if heart involvement or edema. AHAS Journals

• Sugary drinks/ultra-processed foods that promote weight gain and fatigue. AHAS Journals

• High-dose supplements without monitoring (risk of interactions or kidney strain). AHAS Journals

---

FAQs

1) Is LGMDR6 curable?
Not yet. Care focuses on protecting muscles, lungs, and heart and supporting independence. Research into gene-directed and vector-based therapies is active. ScienceDirect

2) Will everyone get heart problems?
No, but cardiomyopathy can occur, so routine heart checks are recommended even if you feel well. PMC+1

3) What tests confirm the diagnosis?
Blood CK, EMG, muscle MRI/biopsy for sarcoglycan staining, and genetic testing for SGCD. Muscular Dystrophy UK

4) Can exercise help or harm?
Gentle, guided exercise helps flexibility and stamina. Avoid high-impact or painful workouts. Muscular Dystrophy Association

5) Are steroids helpful?
Unlike Duchenne, benefits in sarcoglycanopathies are uncertain; use is individualized. NMD Journal

6) What about stem-cell clinics?
Avoid unapproved treatments; discuss only trial-grade options with your team. AHAS Journals

7) How often should I see cardiology?
Typically yearly, sooner with symptoms; frequency is tailored to findings. NMD Journal

8) Do braces or wheelchairs mean “giving up”?
No—these tools extend independence, reduce falls, and save energy. Muscular Dystrophy Association

9) Are there population groups where LGMDR subtypes are more common?
Some sarcoglycanopathies show founder effects; delta-sarcoglycan disease is among the rarest. BioMed Central+1

10) Is LGMDR6 always childhood-onset?
No; onset varies from childhood to adulthood, but earlier onset often means faster progression. Orpha

11) Can I have a healthy pregnancy?
Many can with planning; coordinate closely with neuromuscular, cardiology, and obstetric teams. NMD Journal

12) What should my school/work know?
You may need accommodations for mobility, fatigue, and safety—an OT can help plan this. Muscular Dystrophy Association

13) How common is LGMDR6?
Sarcoglycanopathies are rare; delta-sarcoglycan is the least common subtype. Exact numbers vary by region. BioMed Central+1

14) Are clinical trials available?
Trials exist in LGMD broadly; check registries and neuromuscular centers for SGCD-focused research. ScienceDirect

15) What is the long-term outlook?
Progression is variable. With modern cardiac/respiratory care and rehab, many people maintain quality of life longer. AHAS Journals

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 08, 2025.

PDF Documents For This Disease Condition References